Table 3

Absolute changes between baseline and week 12 in parameters by treatment group

Baseline (week 0)Week 12Adjusted changes (week 12–week 0)
ParameterPlacebo* (n=43)Etanercept* (n=39)Placebo* (n=43)Etanercept* (n=39)Placebo (n=43)Etanercept (n=39)p Value
BASDAI (0–100)58±1564±1245±1937±26−14±20−26±200.008
BASFI (0–100)57±1963±2048±2141±29−10±18−22±180.004
BASMI, (0–10)5.8±1.35.7±1.45.6±1.35.1±1.7−0.20±0.65−0.57±0.650.011
Total back pain, (0–100)61±2070±1648±2238±28−15±24−29±240.010
CRP, mg/l17±1925±3118±206±8−1±14−16±14<0.0001
  • * Data are mean±SD.

  • Data are adjusted mean±SD from a mixed model ANCOVA with an autoregressive correlation structure with treatment groups, visits and their interaction as fixed factors and baseline scores as a covariate.

  • ASDAS-CRP, Ankylosing Spondylitis Disease Activity Score-CRP; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; CRP, C reactive protein.